Signature Estate & Investment Advisors LLC Cuts Holdings in SPDR S&P Biotech (XBI)

Signature Estate & Investment Advisors LLC reduced its position in shares of SPDR S&P Biotech (NYSEARCA:XBI) by 7.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,846 shares of the exchange traded fund’s stock after selling 598 shares during the period. Signature Estate & Investment Advisors LLC’s holdings in SPDR S&P Biotech were worth $679,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Russell Investments Group Ltd. boosted its holdings in shares of SPDR S&P Biotech by 61.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 49,141 shares of the exchange traded fund’s stock worth $3,792,000 after purchasing an additional 18,746 shares during the last quarter. Bray Capital Advisors boosted its holdings in shares of SPDR S&P Biotech by 120.3% during the 2nd quarter. Bray Capital Advisors now owns 15,610 shares of the exchange traded fund’s stock worth $1,205,000 after purchasing an additional 8,525 shares during the last quarter. Boston Advisors LLC acquired a new position in shares of SPDR S&P Biotech during the 2nd quarter worth approximately $213,000. Meridian Wealth Management LLC acquired a new position in shares of SPDR S&P Biotech during the 2nd quarter worth approximately $432,000. Finally, FineMark National Bank & Trust boosted its holdings in shares of SPDR S&P Biotech by 7.4% during the 2nd quarter. FineMark National Bank & Trust now owns 5,210 shares of the exchange traded fund’s stock worth $402,000 after purchasing an additional 360 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Signature Estate & Investment Advisors LLC Cuts Holdings in SPDR S&P Biotech (XBI)” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/14/signature-estate-investment-advisors-llc-cuts-holdings-in-spdr-sp-biotech-xbi.html.

Shares of SPDR S&P Biotech (NYSEARCA XBI) traded down $1.09 during trading on Tuesday, hitting $81.68. The stock had a trading volume of 3,542,500 shares, compared to its average volume of 4,216,511. SPDR S&P Biotech has a fifty-two week low of $58.66 and a fifty-two week high of $88.98.

SPDR S&P Biotech Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply